<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Spence | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/editorevent7/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/editorevent7/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Spence.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">cfa018ebb7894f6205c2099f2f9428cc</guid>
				<title>Spence posted an update: Moreover, the anti-hyperlipidemic effects of sesamin are [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/39693/</link>
				<pubDate>Thu, 06 Feb 2025 09:39:25 -0800</pubDate>

									<content:encoded><![CDATA[<p>Moreover, the anti-hyperlipidemic effects of sesamin are compared to those of other important sesame lignans like sesamolin and episesamin. Findings reveal that sesamin mainly exerts its anti-hyperlipidemic effects by targeting Δ5 desaturase, HMGCR, ABCA1 and ABCG1 through PPARα, PPARγ, LXRα, and SREBP signaling pathways. Overall, the amount of&hellip;<span class="activity-read-more" id="activity-read-more-39693"><a href="http://www.nationalboardinstitute.com/activity/p/39693/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d9dcbc27ecb79737db9bd512b67c4247</guid>
				<title>Spence posted an update: GLP-1 receptor agonists, such as exenatide, have been proven [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38128/</link>
				<pubDate>Tue, 04 Feb 2025 09:39:15 -0800</pubDate>

									<content:encoded><![CDATA[<p>GLP-1 receptor agonists, such as exenatide, have been proven to attenuate nonalcoholic fatty liver disease (NAFLD) in vivo and in vitro. However, the efficiency of exenatide had interindividual differences. PNPLA3 is a major susceptibility gene for NAFLD and its I148M polymorphism increases the risk of all disorders of the NAFLD spectrum. Whether&hellip;<span class="activity-read-more" id="activity-read-more-38128"><a href="http://www.nationalboardinstitute.com/activity/p/38128/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">dd7aa6f31b1c24dd8bb6f9adda427605</guid>
				<title>Spence posted an update: 373; 95% confidence interval, 0.224- 0.622). Every [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34533/</link>
				<pubDate>Fri, 31 Jan 2025 09:33:25 -0800</pubDate>

									<content:encoded><![CDATA[<p>373; 95% confidence interval, 0.224- 0.622). Every 100-morphine milligram equivalent (MME) increase in presurgery use led to a 16% increase in odds of needing &gt;1 opioid refill (adjusted odds ratio= 1.161; 95% confidence interval, 1.085-1.242). Subjects who noted higher satisfaction consumed less overall opioids when receiving a refill (436 vs 1119&hellip;<span class="activity-read-more" id="activity-read-more-34533"><a href="http://www.nationalboardinstitute.com/activity/p/34533/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f0eb1fabe6172b8c8e53fecd35cf14e6</guid>
				<title>Spence posted an update: Gitelman syndrome is a rare autosomal recessive salt-losing [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/33457/</link>
				<pubDate>Thu, 30 Jan 2025 09:27:03 -0800</pubDate>

									<content:encoded><![CDATA[<p>Gitelman syndrome is a rare autosomal recessive salt-losing disorder of renal tubules, which results in hypokalemic metabolic alkalosis. Associated hypomagnesaemia and hypocalcaemia are also seen. Gitelman syndrome is a variant of renal Bartter&#8217;s syndrome. Anaesthetic management of these obstetric patients is challenging and requires a careful&hellip;<span class="activity-read-more" id="activity-read-more-33457"><a href="http://www.nationalboardinstitute.com/activity/p/33457/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ba629b38a51b2eccb788823ddc5bdc61</guid>
				<title>Spence posted an update: To construct a HIV-1 gp120 transgenic mouse model (gp120 [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29527/</link>
				<pubDate>Tue, 28 Jan 2025 13:16:37 -0800</pubDate>

									<content:encoded><![CDATA[<p>To construct a HIV-1 gp120 transgenic mouse model (gp120</p>
<p> ) with </p>
<p> 7 nicotinic acetylcholine receptor (</p>
<p> 7nAChR) gene knockout.</p>
<p> The </p>
<p> 7nAChR gene knockout mice (</p>
<p> 7R</p>
<p> ) were crossed with HIV-1gp120 transgenic mice (gp120</p>
<p> ) to generate F1 generation mice. We selected the F1 mice with the genotype of </p>
<p> 7R&hellip;<span class="activity-read-more" id="activity-read-more-29527"><a href="http://www.nationalboardinstitute.com/activity/p/29527/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">4c39293b8bb556b29b1259d8380c7c4e</guid>
				<title>Spence became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29495/</link>
				<pubDate>Tue, 28 Jan 2025 13:13:38 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>